P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000969096.68540.54 |
| _version_ | 1797279906754723840 |
|---|---|
| author | Jacopo Nanni Antonino Mulè Ernesta Audisio Maria Paola Martelli Barbara Scappini Elisabetta Petracci Irene Valli Irene Azzali Chiara Zingaretti Maria Benedetta Giannini Simona Sica Benedetta Cambò Anna Candoni Monia Lunghi Francesco Albano Attilio Olivieri Nicola Fracchiolla Gian Matteo Rigolin Massimo Bernardi Claudio Romani Elisabetta Todisco Federica Gigli Monica Bocchia Daniela Cilloni Nicola DI Renzo Daniele Vallisa Anna Maria Mianulli Alessandro Cignetti Francesco Lanza Valentina Robustelli Giorgia Simonetti Maria Teresa Bochicchio Giovanni Marconi The Flam Collaborative Group Cristina Papayannidis Giovanni Martinelli |
| author_facet | Jacopo Nanni Antonino Mulè Ernesta Audisio Maria Paola Martelli Barbara Scappini Elisabetta Petracci Irene Valli Irene Azzali Chiara Zingaretti Maria Benedetta Giannini Simona Sica Benedetta Cambò Anna Candoni Monia Lunghi Francesco Albano Attilio Olivieri Nicola Fracchiolla Gian Matteo Rigolin Massimo Bernardi Claudio Romani Elisabetta Todisco Federica Gigli Monica Bocchia Daniela Cilloni Nicola DI Renzo Daniele Vallisa Anna Maria Mianulli Alessandro Cignetti Francesco Lanza Valentina Robustelli Giorgia Simonetti Maria Teresa Bochicchio Giovanni Marconi The Flam Collaborative Group Cristina Papayannidis Giovanni Martinelli |
| author_sort | Jacopo Nanni |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:33:40Z |
| format | Article |
| id | doaj.art-9a5a56296c7548258e3fc905755c4710 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:33:40Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-9a5a56296c7548258e3fc905755c47102024-03-03T10:07:31ZengWileyHemaSphere2572-92412023-08-017e685405410.1097/01.HS9.0000969096.68540.54202308003-00448P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTINGJacopo Nanni0Antonino Mulè1Ernesta Audisio2Maria Paola Martelli3Barbara Scappini4Elisabetta Petracci5Irene Valli6Irene Azzali7Chiara Zingaretti8Maria Benedetta Giannini9Simona Sica10Benedetta Cambò11Anna Candoni12Monia Lunghi13Francesco Albano14Attilio Olivieri15Nicola Fracchiolla16Gian Matteo Rigolin17Massimo Bernardi18Claudio Romani19Elisabetta Todisco20Federica Gigli21Monica Bocchia22Daniela Cilloni23Nicola DI Renzo24Daniele Vallisa25Anna Maria Mianulli26Alessandro Cignetti27Francesco Lanza28Valentina Robustelli29Giorgia Simonetti30Maria Teresa Bochicchio31Giovanni Marconi32The Flam Collaborative Group33Cristina Papayannidis34Giovanni Martinelli351 Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Bologna, Italy2 U.O.C. di Oncoematologia, A.O.O.R. Villa Sofia – Cervello, Palermo, Italy3 SC Ematologia 2, Dipartmento di Ematologia e Oncologia, AO Città della Salute e della Scienza, Torino, Italy4 Institute of Hematology and Center for Hemato-Oncology Research, University of Perugia and Santa Maria della Misericordia Hospital, Perugia, Italy5 AOU Careggi, SODc Ematologia, Firenze, Italy; Sezione di Ematologia6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy7 Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Roma, Italy8 Department of Medicine and Surgery, Hematology and BMT Unit, University of Parma, Parma, Italy9 Clinica Ematologica Azienda Sanitaria Universitaria Integrata di Udine, Italy10 Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy11 Hematology and Stem cell Transplantation Unit - Department of Emergency and Organ Transplantation (D.E.T.O.) - University of Bari, Italy12 Clinica di Ematologia AOU Ospedali Riuniti di Ancona, Italy13 Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico di Milano14 Hematology, St. Anna University Hospital, Cona, Ferrara, Italy15 IRCCS, Ospedale San Raffaele s.r.l U.O. Ematologia e TMO Milano, Italy16 SC Ematologia e CTMO, Azienda Ospedaliera Brotzu, Cagliari, Italy17 European Institute of Oncology, Milano, Italy17 European Institute of Oncology, Milano, Italy18 Hematology Unit, University of Siena, Siena, Italy19 Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, S.S.D Terapia onco-ematologica intensiva e trapianto CSE, AOU San Luigi Gonzaga, Orbassano (TO), Italy20 Unità di Ematologia e TCS, Ospedale “Vito Fazzi”, Lecce, Italy21 UO Ematologia e CTMO, Ospedale G. da Saliceto, Piacenza, Italia22 Ospedale Infermi, AUSL Romagna, UO Ematologia, Rimini, Italy23 Divisione Universitaria di Ematologia e Terapie Cellulari, A.O. Ordine Mauriziano, Torino, Italy24 Ospedale Santa Maria delle Croci, AUSL Romagna, UO Ematologia, Ravenna, Italy1 Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Bologna, Italy6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italy25 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy6 IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”, Meldola, Italyhttp://journals.lww.com/10.1097/01.HS9.0000969096.68540.54 |
| spellingShingle | Jacopo Nanni Antonino Mulè Ernesta Audisio Maria Paola Martelli Barbara Scappini Elisabetta Petracci Irene Valli Irene Azzali Chiara Zingaretti Maria Benedetta Giannini Simona Sica Benedetta Cambò Anna Candoni Monia Lunghi Francesco Albano Attilio Olivieri Nicola Fracchiolla Gian Matteo Rigolin Massimo Bernardi Claudio Romani Elisabetta Todisco Federica Gigli Monica Bocchia Daniela Cilloni Nicola DI Renzo Daniele Vallisa Anna Maria Mianulli Alessandro Cignetti Francesco Lanza Valentina Robustelli Giorgia Simonetti Maria Teresa Bochicchio Giovanni Marconi The Flam Collaborative Group Cristina Papayannidis Giovanni Martinelli P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING HemaSphere |
| title | P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING |
| title_full | P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING |
| title_fullStr | P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING |
| title_full_unstemmed | P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING |
| title_short | P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING |
| title_sort | p547 upfront intensive treatment analysis of the italian cohort study on flt3 mutated aml patients flam the impact of a flt3 inhibitor addition to standard chemotherapy in the real life setting |
| url | http://journals.lww.com/10.1097/01.HS9.0000969096.68540.54 |
| work_keys_str_mv | AT jacoponanni p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT antoninomule p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT ernestaaudisio p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT mariapaolamartelli p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT barbarascappini p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT elisabettapetracci p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT irenevalli p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT ireneazzali p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT chiarazingaretti p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT mariabenedettagiannini p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT simonasica p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT benedettacambo p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT annacandoni p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT monialunghi p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT francescoalbano p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT attilioolivieri p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT nicolafracchiolla p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT gianmatteorigolin p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT massimobernardi p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT claudioromani p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT elisabettatodisco p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT federicagigli p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT monicabocchia p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT danielacilloni p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT nicoladirenzo p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT danielevallisa p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT annamariamianulli p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT alessandrocignetti p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT francescolanza p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT valentinarobustelli p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT giorgiasimonetti p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT mariateresabochicchio p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT giovannimarconi p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT theflamcollaborativegroup p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT cristinapapayannidis p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting AT giovannimartinelli p547upfrontintensivetreatmentanalysisoftheitaliancohortstudyonflt3mutatedamlpatientsflamtheimpactofaflt3inhibitoradditiontostandardchemotherapyinthereallifesetting |